MMG
, a global health communications company specializing in clinical trial patient recruitment and retention, has formed an exclusive partnership with
Remedy Health Media
to deliver access to a larger pool of qualified potential clinical trial participants. Remedy Health Media (Remedy) is a health information and technology company, which produces a variety of clinical and wellness resources including Remedy’s Healthy Living and Diabetes Focus and maintains publishing partnerships with globally recognized institutions such as Johns Hopkins Medicine and the University of California, Berkeley School of Public Health.
This partnership offers value to MMG’s clients by effectively reaching their desired audiences through Remedy’s community of more than 150 million health-information-seeking patients and caregivers. Remedy’s 28.4 million unique monthly visitors (comScore, September 2012) proactively seek treatment options for therapeutic areas that match MMG’s category coverage.
Additional benefits for MMG’s clients include:
· Guaranteed increase in already-high number of patient referrals;
· Strengthened patient retention rate through Remedy’s HIPAA-compliant, proprietary mobile content and adherence tools; and
· Exclusive media placement capabilities.
“We were drawn to this partnership with Remedy because we want to be able to provide information to patients faster while offering our clients even higher value for their investment,” said John Benbrook, CEO of MMG. “We look forward to leveraging MMG’s unique presence within Remedy’s expansive network of trusted health resources to deliver even greater measurable results.”
Michael Cunnion, CEO of Remedy Health Media, said, “We’re thrilled to partner with MMG because this is a perfect opportunity to provide better information, tools and connectivity to patients who are actively seeking clarity in the trial enrollment process.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.